Frequently Asked Questions:
The COVID-19 pandemic outbreak has increased the market for artificial pancreas device systems. Globally, the Intensive Care Units (ICU) are inundated by the COVID-19 patients.
North America accounted for the most heightened share in the global artificial pancreas device systems market.
One of the main factors propelling the market’s expansion is the rising incidence of chronic diseases like pancreatitis, pancreatic cancer, and other similar conditions.
The control-to-target (CTT) systems segment had a major share in the global market in 2022.